Abstract: The present invention demonstrated a Cre-loxP based cofilin-1 transgenic animal model to address the pathophysiological role of over-expressed cofilin-1 on systemic development.

Abstract: A display device includes a substrate, a first light emitting element, a second light emitting element, and an optical film sheet. The first light emitting element and the second light emitting element are disposed on the substrate. The first light emitting element emits a first light, and the first light has a first wavelength range. The second light emitting element emits a second light, and the second light has a second wavelength range. The optical film sheet is disposed above the first light emitting element and the second light emitting element. The optical film sheet includes a first zone and a second zone. The first zone includes a first cholesteric liquid crystal, and the first cholesteric liquid crystal reflects light in at least the first wavelength range. The second zone includes a second cholesteric liquid crystal, and the second cholesteric liquid crystal reflects light in at least the second wavelength range.

Abstract: A system for recognizing abnormal activity of human body using wearable electronic device and mixed reality technology, includes a first wearable electronic device, a plurality of second wearable electronic devices, at least one camera, and a judgement module. The system is suitable to be applied in any type of work environment, so as to monitor and determine whether a user (i.e., an operator or an employee) exhibits abnormal activities by referring a document of standard operating procedures (SOP), an operating manual and a document of safety operation standard (SOS), to reduce a rate of user mishandling, thereby achieving the enhancement of work efficiency and productivity.

Abstract: A machine failure analyzing system includes a wearable electronic device is for a user to wear, a controlling and processing device provided with a machine history database and a failure causes analyzing unit. When a specific machine is malfunctioning or in a failure status, the controlling and processing device utilizes a machine status data collecting unit to collect machine status data from the specific machine. Subsequently, based on the machine status data, the failure causes analyzing unit is configured to find relative failure causes from the machine history database, thereby generating at least one troubleshooting solution. As such, under instructions of the troubleshooting solution, a field engineer who wears the wearable electronic device can achieve troubleshooting of the specific machine rapidly and precisely, without needing to spend time finding the failure causes.

Abstract: Disclosures of the present invention describe a system for recognizing abnormal activity of human body using wearable electronic device and mixed reality technology, comprising: a first wearable electronic device, a plurality of second wearable electronic devices, at least one camera, and a judgement module. This novel system is suitable for applying in any kinds of work environment, so as to monitor and determine whether a user (i.e., an operator or an employee) exhibits abnormal activities by referring a document of standard operating procedures (SOP), an operating manual and a document of safety operation standard (SOS), such that it is facilitated to reduce a happening rate of the user's mishandling, thereby achieving the enhancement of work efficiency and productivity.

Abstract: Disclosures of the present invention describe a machine failure analyzing system. In the machine failure analyzing system, a wearable electronic device is for a user to wear, and a controlling and processing device is provided with a machine history data base and a failure causes analyzing unit. When a specific machine is malfunctioning or in a failure status, the controlling and processing device utilizes a machine status data collecting unit to collect machine status data from the specific machine. Subsequently, based on the machine status data, the failure causes analyzing unit can find relative failure causes from the machine history data base, thereby generating at least one troubleshooting solution. As such, under instructions of the troubleshooting solution, a field engineer who wears the wearable electronic device can achieve the troubleshooting of the specific machine rapidly and precisely, without needing to spend time finding the failure causes.

Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.

Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.

Abstract: The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Abstract: A sustained release composition comprising a polymer and manufacturing method thereof. The sustained release composition comprises a polymer, a bioactive agent, and a release rate determined agent, wherein the release rate determined agent is dispersed in the sustained release composition to control the release rate of the bioactive agent. The method comprises providing an oil phase comprising a bioactive agent, a polymer, and a release rate determined agent; providing an aqueous phase comprising a surfactant; mixing the oil phase with the aqueous phase to form the sustained release composition having a controlled release effect.

Abstract: A stationary exercise apparatus includes a frame, a driving wheel assembly, two treading units, and a flywheel assembly. The flywheel assembly has a driven wheel. The driven wheel and the driving wheel assembly are positioned coaxially and pivotally. The treading units are arranged in a four-link manner and can actuate the driving wheel assembly. The driving wheel assembly drives the driven wheel to rotate at an inertial operating speed higher than the rotation speed of the driving wheel assembly. After being actuated, the stationary exercise apparatus operates continuously because of inertial rotation of the driven wheel. During their operation, pedals of the treading units keep lying on the same horizontal plane to thereby enable the user to tread smoothly and lower the prevalence of sports injuries.

Abstract: The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C4-C20 alkane, wherein the modified histidine and the polymer or C4-C20 alkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C4-C20 alkane is about 0-40%.

Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.

Abstract: The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Abstract: A stationary exercise apparatus includes a frame, a driving wheel assembly, two treading units, and a flywheel assembly. The flywheel assembly has a driven wheel. The driven wheel and the driving wheel assembly are positioned coaxially and pivotally. The treading units are arranged in a four-link manner and can actuate the driving wheel assembly. The driving wheel assembly drives the driven wheel to rotate at an inertial operating speed higher than the rotation speed of the driving wheel assembly. After being actuated, the stationary exercise apparatus operates continuously because of inertial rotation of the driven wheel. During their operation, pedals of the treading units keep lying on the same horizontal plane to thereby enable the user to tread smoothly and lower the prevalence of sports injuries.

Abstract: A controllable release composition is provided, including a polymer substrate and an active ingredient, in which the polymer substrate is a polymer blend including a biodegradable polyester, polyanhydride, and/or polyether, and the active ingredient includes a radioactive agent or a chemotherapeutic agent. The controllable release composition is useful for cancer therapy, particularly for solid cancer treatment.

Abstract: A sustained release composition comprising a polymer and manufacturing method thereof. The sustained release composition comprises a polymer, a bioactive agent, and a release rate determined agent, wherein the release rate determined agent is dispersed in the sustained release composition to control the release rate of the bioactive agent. The method comprises providing an oil phase comprising a bioactive agent, a polymer, and a release rate determined agent; providing an aqueous phase comprising a surfactant; mixing the oil phase with the aqueous phase to form the sustained release composition having a controlled release effect.